IOVA - Iovance Biotherapeutics, Inc.
| Previous Close | 15.10 |
| Open | 14.95 |
| Bid | 14.60 x 700 |
| Ask | 17.90 x 1200 |
| Day's Range | 14.80 - 15.25 |
| 52 Week Range | 4.45 - 19.90 |
| Volume | 306,994 |
| Avg. Volume | 1,163,874 |
| Market Cap | 1.333B |
| Beta | 3.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.41 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.14 |
- GlobeNewswire•18 days ago
Report: Developing Opportunities within Enanta Pharmaceuticals, ServisFirst Bancshares, Lion Biotechnologies, Peapack-Gladstone Financial, Analogic, and Akcea Therapeutics — Future Expectations, Projections Moving into 2018
NEW YORK, April 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Associated Press•last month
Iovance Biotherapeutics posts 4Q loss
On a per-share basis, the San Carlos, California-based company said it had a loss of 36 cents. Losses, adjusted for stock option expense, came to 32 cents per share. The results met Wall Street expectations. ...
- GlobeNewswire•last month
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
SAN CARLOS, Calif., March 12, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today reported its ...
- ACCESSWIRE•last month
Iovance Biotherapeutics Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Iovance Biotherapeutics Inc (NASDAQ: IOVA ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018, at 4:30 PM Eastern ...
- GlobeNewswire•last month
Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and Provide a Corporate Update on Monday, March 12, 2018
SAN CARLOS, Calif., March 08, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...
- GlobeNewswire•2 months ago
Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in March
SAN CARLOS, Calif., March 07, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...
- PR Newswire•2 months ago
Johnson Fistel, LLP Announces Investigations of RH, WageWorks, Inc., BRF S.A., and Iovance Biotherapeutics, Inc.; Investors Encouraged to Contact Firm
SAN DIEGO , March 6, 2018 /PRNewswire/ --Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against RH, WageWorks, Inc., BRF S.A., and Iovance Biotherapeutics, Inc., as detailed ...
- Zacks•2 months ago
Is a Surprise Coming for Lion Biotechnologies (IOVA) This Earnings Season?
Lion Biotechnologies (IOVA) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
- PR Newswire•2 months ago
IOVANCE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. - IOVA
NEW ORLEANS , March 2, 2018 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF ...
- GlobeNewswire•2 months ago
Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors
SAN CARLOS, Calif., March 01, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced the ...
- Business Wire•2 months ago
IOVANCE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. – IOVA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Iovance Biotherapeutics, Inc.
- TheStreet.com•2 months ago
Biotech Heats Up as Fear of Missing Out Returns
It's hard to believe the bounce will continue to run in V-shaped fashion.
- GlobeNewswire•2 months ago
Iovance Biotherapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
SAN CARLOS, Calif., Feb. 14, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...
- Simply Wall St.•3 months ago
Iovance Biotherapeutics Inc (NASDAQ:IOVA) And The Healthcare Sector Outlook 2018
Iovance Biotherapeutics Inc (NASDAQ:IOVA), a $1.45B small-cap, operates in the healthcare industry, which faces demand for new drug development to meet new or persistent chronic illnesses, and ongoing need forRead More...
- Zacks•3 months ago
Iovance Biotherapeutics (IOVA) in Focus: Stock Moves 5.1% Higher
Iovance Biotherapeutics (IOVA) shares rose more than 5% in the last trading session, amid huge volumes.
- GlobeNewswire•3 months ago
Iovance Biotherapeutics, Inc. Announces Closing of $172.5 Million Common Stock Public Offering
SAN CARLOS, Calif., Jan. 29, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced the ...
- Motley Fool•3 months ago
Why W.W. Grainger, Iovance Biotherapeutics, and Dolby Laboratories Jumped Today
These stocks stood out on a good day for Wall Street. Find out why.
- Motley Fool•3 months ago
Here's Why Iovance Biotherapeutics Rose as Much as 29.1% Today
Investors are cheering recently released phase 2 data.
- GlobeNewswire•3 months ago
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
SAN CARLOS, Calif., Jan. 25, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced the ...
- GlobeNewswire•3 months ago
Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock
SAN CARLOS, Calif., Jan. 24, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...
- GlobeNewswire•3 months ago
Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers
Three of Eight Evaluable Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with LN-145 Experienced a Confirmed Partial Response One of Two Evaluable Patients ...
- Business Wire•3 months ago
IOVANCE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. – IOVA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Iovance Biotherapeutics, Inc.
GuruFocus.com•3 months agoFledgling Biotech Company's Stock Surges
Iovance Biotherapeutics develops cancer immunotherapy treatments
- PR Newswire•3 months ago
IOVANCE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. - IOVA
NEW ORLEANS , Jan. 12, 2018 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF ...
- ACCESSWIRE•3 months ago
Update in Lawsuit for Investors in Shares of Iovance Biotherapeutics, Inc (NASDAQ: IOVA), formerly Lion Biotechnologies, Inc. Announced by Shareholders Foundation
SAN DIEGO, CA / ACCESSWIRE / January 10, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain purchasers of shares against Iovance Biotherapeutics, Inc. (formerly NASDAQ: ...
